scholarly journals Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves the erythrocyte phenotype in murine beta- thalassemia

Blood ◽  
1994 ◽  
Vol 84 (3) ◽  
pp. 928-933 ◽  
Author(s):  
JL Villeval ◽  
P Rouyer-Fessard ◽  
N Blumenfeld ◽  
A Henri ◽  
W Vainchenker ◽  
...  

Abstract Repeated injections of large doses of erythropoietin (Epo) have been shown to be of benefit in the treatment of murine and human beta- thalassemia. To determine whether Epo gene therapy could replace this treatment for long-term periods, lethally irradiated beta-thalassemic (Hbbd3th haplotype) and normal DBA/2J (Hbbd haplotype) mice were grafted with syngeneic bone marrow cells infected with a retroviral vector carrying the Epo cDNA. In normal mice, dysregulated Epo production induced elevated serum Epo levels (176 +/- 68 mU/mL), high hematocrit levels (73% +/- 8%), and elevated beta-minor globin chain synthesis. In contrast, in thalassemic mice, moderate increases in the hematocrit levels (from 33% +/- 1% to 43% +/- 9%), associated with limited increases in the initially elevated Epo levels (from 83 +/- 22 to 190 +/- 230 mU/mL), were recorded 2 months after transplantation. In mice in which the hematocrit increased most, from 33% +/- 1% before transplantation to 49% +/- 10%, the retroviral Epo gene expression induced a striking improvement of the beta-thalassemic syndrome. These mice exhibited normal or near-normal beta/alpha-globin chain synthesis ratios, induced by the activation of the beta-minor chain. This led to the elimination of the high amounts of unpaired alpha chains in erythrocytes and finally reduced the reticulocyte count despite the permanent Epo stimulation. These results show that efficient Epo gene expression corrects the erythrocyte phenotype of the mouse beta- thalassemic syndrome. However, the incidence of lethal polycythemia or of transient improvements indicates that the present strategy is only the first step toward such indirect gene therapy.

Blood ◽  
1994 ◽  
Vol 84 (3) ◽  
pp. 928-933 ◽  
Author(s):  
JL Villeval ◽  
P Rouyer-Fessard ◽  
N Blumenfeld ◽  
A Henri ◽  
W Vainchenker ◽  
...  

Repeated injections of large doses of erythropoietin (Epo) have been shown to be of benefit in the treatment of murine and human beta- thalassemia. To determine whether Epo gene therapy could replace this treatment for long-term periods, lethally irradiated beta-thalassemic (Hbbd3th haplotype) and normal DBA/2J (Hbbd haplotype) mice were grafted with syngeneic bone marrow cells infected with a retroviral vector carrying the Epo cDNA. In normal mice, dysregulated Epo production induced elevated serum Epo levels (176 +/- 68 mU/mL), high hematocrit levels (73% +/- 8%), and elevated beta-minor globin chain synthesis. In contrast, in thalassemic mice, moderate increases in the hematocrit levels (from 33% +/- 1% to 43% +/- 9%), associated with limited increases in the initially elevated Epo levels (from 83 +/- 22 to 190 +/- 230 mU/mL), were recorded 2 months after transplantation. In mice in which the hematocrit increased most, from 33% +/- 1% before transplantation to 49% +/- 10%, the retroviral Epo gene expression induced a striking improvement of the beta-thalassemic syndrome. These mice exhibited normal or near-normal beta/alpha-globin chain synthesis ratios, induced by the activation of the beta-minor chain. This led to the elimination of the high amounts of unpaired alpha chains in erythrocytes and finally reduced the reticulocyte count despite the permanent Epo stimulation. These results show that efficient Epo gene expression corrects the erythrocyte phenotype of the mouse beta- thalassemic syndrome. However, the incidence of lethal polycythemia or of transient improvements indicates that the present strategy is only the first step toward such indirect gene therapy.


Blood ◽  
1983 ◽  
Vol 62 (5) ◽  
pp. 1035-1040 ◽  
Author(s):  
R Galanello ◽  
R Ruggeri ◽  
E Paglietti ◽  
M Addis ◽  
MA Melis ◽  
...  

Abstract In this article we report a Sardinian family, in which a beta- thalassemia gene and a triple alpha-globin loci, counterpart of the rightward deletion type alpha-thalassemia-2, were segregating. The analysis of the genotype-phenotype correlations in the different family members allowed us to give an outline of the manifestations associated with different genotype combinations. The heterozygote for the triple alpha-loci showed no consistent abnormal clinical or hematologic characteristics and presented balanced alpha/beta-globin chain synthesis. In the homozygous state for this lesion, the only phenotypic expression was a slightly imbalanced globin chain synthesis. The combination of heterozygous beta-thalassemia with the heterozygous state for the triple alpha-globin loci produced no clinical manifestations and showed a hematologic phenotype indistinguishable from that of heterozygous beta-thalassemia. On the other hand, the combination of the homozygous state for the triple alpha-globin gene loci and the heterozygous state for beta-thalassemia produced a clinical picture of thalassemia intermedia with a very mild clinical course, minor increase of fetal hemoglobin (HbF) levels, and a pronounced imbalance of globin chain synthesis.


Blood ◽  
1983 ◽  
Vol 62 (5) ◽  
pp. 1035-1040
Author(s):  
R Galanello ◽  
R Ruggeri ◽  
E Paglietti ◽  
M Addis ◽  
MA Melis ◽  
...  

In this article we report a Sardinian family, in which a beta- thalassemia gene and a triple alpha-globin loci, counterpart of the rightward deletion type alpha-thalassemia-2, were segregating. The analysis of the genotype-phenotype correlations in the different family members allowed us to give an outline of the manifestations associated with different genotype combinations. The heterozygote for the triple alpha-loci showed no consistent abnormal clinical or hematologic characteristics and presented balanced alpha/beta-globin chain synthesis. In the homozygous state for this lesion, the only phenotypic expression was a slightly imbalanced globin chain synthesis. The combination of heterozygous beta-thalassemia with the heterozygous state for the triple alpha-globin loci produced no clinical manifestations and showed a hematologic phenotype indistinguishable from that of heterozygous beta-thalassemia. On the other hand, the combination of the homozygous state for the triple alpha-globin gene loci and the heterozygous state for beta-thalassemia produced a clinical picture of thalassemia intermedia with a very mild clinical course, minor increase of fetal hemoglobin (HbF) levels, and a pronounced imbalance of globin chain synthesis.


Blood ◽  
1972 ◽  
Vol 40 (1) ◽  
pp. 105-111 ◽  
Author(s):  
Mordechai Shchory ◽  
Bracha Ramot

Abstract α, β, and γ globin chain synthesis in bone marrow and peripheral blood reticulocytes were studied in two patients with thalassemia major, two with thalassemia intermedia, one with thalassemia minor, one with Hb H disease, and one with homozygous βδ-thalassemia. Nine nonthalassemic patients served as controls. In thalassemia major, a marked imbalance of α- to β-chain synthesis was found in the bone marrow as well as in reticulocytes. The imbalance, however, was slightly more evident in the latter. In the patients with thalassemia intermedia and minor the α- to β-globin chain ratios in the reticulocytes were of the same order of magnitude, despite the marked clinical differences between thalassemia intermedia and minor. A balanced synthesis was found in the bone marrow of the patient with thalassemia minor. The bone marrow globin synthesis in thalassemia intermedia was not studied. Contrary to that in Hb H disease and βδ-thalassemia, the imbalance was more apparent in the bone marrow. In the latter, no evidence for imbalance was detected in the reticulocytes. These results point out the need for further studies on globin chain synthesis in the bone marrow and reticulocytes of patients With the various thalassemia syndromes and the effect of the free globin chain pool on those results.


Blood ◽  
1983 ◽  
Vol 62 (2) ◽  
pp. 341-345 ◽  
Author(s):  
M Pirastu ◽  
R Galanello ◽  
MA Melis ◽  
C Brancati ◽  
A Tagarelli ◽  
...  

Abstract We have defined a new type of delta-thalassemia in which beta-globin chain synthesis is incompletely suppressed. Homozygotes have unusually low HbA2 levels, and double heterozygosity for this delta-thalassemia gene and beta-thalassemia normalizes the HbA2 level. The delta- thalassemia occurs on a chromosome that is identifiable using polymorphic restriction endonuclease sites. We call this condition delta +-thalassemia, to distinguish it from the previously described delta 0-thalassemia syndromes in which no delta-globin chain synthesis occurs.


Blood ◽  
1976 ◽  
Vol 47 (1) ◽  
pp. 113-120 ◽  
Author(s):  
RF Rieder

Abstract A 23-yr-old man of Greek-Italian ancestry with mild anemia was found to be heterozygous for HbD (Punjab) beta121 glu leads to gin and beta- thalassemia. HbA was not detected upon electrophoresis of the subject's hemolysate, and no synthesis of betaA globin was demonstrated after incubation of peripheral blood or bone marrow with 3H-leucine. The thalassemia gene was thus of the betao variety. The betaD/alpha synthesis ratios were almost equally unbalanced in the blood and bone marrow: 0.53 and 0.61, respectively. The mother of the propositus had beta-thalassemia trait. In peripheral blood the betaA/alpha synthesis ratio was 0.38. The mutant betaD gene thus appeared potentially capable of directing the synthesis of globin chains as efficiently as a normal betaA gene. The mildness of the HbD-betao-thalassemia syndrome appeared to be due to the maintenance of a relatively high total beta/alpha synthesis ratio in the presence of a physiologically neutral structural mutation.


Blood ◽  
1991 ◽  
Vol 78 (6) ◽  
pp. 1596-1602 ◽  
Author(s):  
K Leroy-Viard ◽  
P Rouyer-Fessard ◽  
Y Beuzard

Homozygous beta thalassemic mice received 50 U (1,660 U/kg) of recombinant human erythropoietin (rhEpo) 5 days a week for 2 weeks. Hemoglobin increased from 9.2 +/- 0.6 g/dL to 10.5 +/- 0.4 g/dL (P = .002) and hematocrit increased from 29.2% +/- 0.9% to 34.1% +/- 1.9% (P = .0014). The beta minor/alpha globin chain synthesis ratio increased slightly but significantly between day -4 (0.75 +/- 0.07) and day 4 (0.81 +/- 0.04) (P = .01) and reached a minimum ratio (0.67 +/- 0.03) on day 15 (P = .001), being parallel to reticulocyte counts and to the incorporated trichloracetic acid (TCA)-insoluble radioactivity, therefore parallel to the erythropoietic output in thalassemic mice, as in normal mice. Erythrocyte defects were improved in beta thalassemic mice treated by rhEpo: membrane-associated alpha globin was significantly decreased (P less than .01), thiol group reactivity of ankyrin was significantly improved (P less than .05), spectrin alterations were reduced, and deformability of mouse thalassemic red blood cells was normalized. These results provide experimental criteria for modulating globin chain imbalance necessary for the therapy of human beta thalassemia intermedia, and suggest that rhEpo might be of interest to improve the red blood cell mass and reduce erythrocyte alterations in this disease.


Blood ◽  
1976 ◽  
Vol 47 (1) ◽  
pp. 113-120
Author(s):  
RF Rieder

A 23-yr-old man of Greek-Italian ancestry with mild anemia was found to be heterozygous for HbD (Punjab) beta121 glu leads to gin and beta- thalassemia. HbA was not detected upon electrophoresis of the subject's hemolysate, and no synthesis of betaA globin was demonstrated after incubation of peripheral blood or bone marrow with 3H-leucine. The thalassemia gene was thus of the betao variety. The betaD/alpha synthesis ratios were almost equally unbalanced in the blood and bone marrow: 0.53 and 0.61, respectively. The mother of the propositus had beta-thalassemia trait. In peripheral blood the betaA/alpha synthesis ratio was 0.38. The mutant betaD gene thus appeared potentially capable of directing the synthesis of globin chains as efficiently as a normal betaA gene. The mildness of the HbD-betao-thalassemia syndrome appeared to be due to the maintenance of a relatively high total beta/alpha synthesis ratio in the presence of a physiologically neutral structural mutation.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4271-4271
Author(s):  
Donald Lavelle ◽  
Yogenthiran Saunthararajah ◽  
Nadim Mahmud ◽  
Vinzon Ibanez ◽  
Maria Armila Ruiz ◽  
...  

Abstract Abstract 4271 Background: During adult erythroid differentiation, there is a period of transient γ-globin (HBG) gene expression that coincides with transient DNA hypomethylation of the HBG gene promoter. This precedes the final pattern of high β-globin (HBB) gene expression in terminally differentiated adult erythroid cells (the ‘maturational switch’). Possibly, the micro-environment can modulate the period of transient HBG promoter hypomethylation and gene expression, which could have implications for efforts to sustain HBG expression for therapeutic objectives. To evaluate the responsiveness of the maturational switch to external factors, CD34+ hematopoietic progenitor cells from adult baboon bone marrow were cultured with and without AFT024 murine fetal liver stromal cell line feeder layers, as the micro-environmental variable. Methods: All cultures contained Iscove's media with 30% fetal bovine serum, 200ng/ml stem cell factor, 2U/ml erythropoietin, and 1μM dexamethasone. Globin chain synthesis was measured by biosynthetic radiolabelling of globin chains on d11 and d14 followed by HPLC separation, HBG transcript levels were determined by real time PCR, and F cells were analyzed by flow cytometry. Results: γ-globin chain synthesis was significantly lower in the presence of AFT024 feeder layers (0.07±0.05 γ/γ+β, n=4 versus 0.34±0.09 γ/γ+β, n=4, mean±SD, p<0.01). HBG mRNA was also significantly lower in the presence of AFT024 feeder layers (0.09±0.05 γ/total β-like globin mRNA, n=3, versus 0.32±0.10 γ/total β-like globin mRNA, n=3, p<0.025). Accordingly, F cell numbers were substantially decreased in the presence of feeder layers (38 versus 64%). Cell growth was similar in the presence and absence of feeder layers (115±48 versus 86±8.5 fold expansion, n=3). To test whether decreased γ-globin expression in the presence of ATF024 feeder cells is secondary to preferential expansion of more differentiated progenitors less capable of HBG expression, BM cells were fractionated into CD34+ CD36+ and CD34+ CD36- subpopulations prior to culture with and without feeder layers. Expression of HBG in both subpopulations was similarly reduced by the feeder layers, suggesting that decreased HBG expression was due to a direct effect of the feeder layer rather than to selective expansion of a more differentiated subpopulation. Bisulfite sequence analysis was performed to determine if differences in HBG expression were associated with differences in DNA methylation. DNA methylation of 5 CpG residues in the HBG promoter in purified erythroid cells from two independent cultures was 97.6 and 97.7% in the presence of feeder layers and 68.6 and 69.7% without feeder layers. Addition of the DNA methyltransferase inhibitor decitabine (0.5 × 10-6 M), to cells cultured in the presence of feeder layers increased γ-globin synthesis nearly tenfold (0.60 γ/γ+β) compared to untreated controls (0.063 γ/γ+β), consistent with mechanistic role for DNA methylation in HBG repression associated with feeder layer culture. In contrast to the results with adult-derived CD34+ BM cells, cord blood derived CD34+ cells sustained high levels of HBG expression (0.84 γ/γ+β)in the presence of feeder layers. Conclusion: The switch from HBG to HBB gene expression that occurs during the differentiation of adult erythroid cells is responsive to the micro-environment. Furthermore, this switch depends on DNA methylation, and depleting DNMT1 counteracts the micro-environmentally induced switch to sustain γ-globin expression in adult erythroid cells. In contrast to adult erythroid cells, fetal erythroid cells were resistant to micro-environmental induction of a HBG to HBB switch, consistent with previous studies showing that intrinsic differences between adult and fetal erythroid cells are a critical component in developmental stage-specific differences in globin gene expression. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document